Farhad Al Marzook
Farhad Al Marzook has a total of 21 co-authors. Here are the top co-authors by number of shared publications:
Pouya Alijanipour
Department of Orthopedic Sciences and Rehabilitation, University of Texas Medical Branch, Galveston, TX
2 shared publications- Reyhan Meetheen
University of Incarnate Word, School of Osteopathic Medicine, San Antonio, Texas
2 shared publications - Abbas A. Karim
John Sealy School of Medicine, University of Texas of Medical Branch (UTMB) , Galveston, TX 77555
1 shared publication Ahad A. Kesaria
John Sealy School of Medicine
1 shared publication- Ahad A. Kesaria
John Sealy School of Medicine, The University of Texas Medical Branch, Galveston, Texas
1 shared publication - Amina El Ayadi
Department of Surgery, The University of Texas Medical Branch, Galveston, TX 77555, USA
1 shared publication
Latest Publications
- Open Access
- 14 July 2026
- Published by Elsevier in Journal of Shoulder and Elbow Arthroplasty
- Vol. 10 (4)
Pre-operative injectable testosterone therapy is associated with increased five-year revision risk after total shoulder arthroplasty: a TriNetX database analysis
- 14 July 2026
- Published by Elsevier in Journal of Shoulder and Elbow Arthroplasty
- Vol. 10 (4)
Open AccessPre-operative injectable testosterone therapy is associated with increased five-year revision risk after total shoulder arthroplasty: a TriNetX database analysis
- 29 June 2026
- Published by Wolters Kluwer Health in Clinical Spine Surgery
Preoperative Use of GLP-1 Receptor Agonists Is Associated With Reduced Risk of Postoperative DVT and Mortality in Patients Undergoing Lumbar Laminectomy
Study Design: Retrospective cohort study. Objective: To evaluate the association between preoperative glucagon-like peptide-1 receptor agonist (GLP-1 RA) use and postoperative outcomes in patients undergoing lumbar laminectomy. Summary of Background Data: GLP-1 RAs have gained prominence for their weight management benefits. Emerging evidence suggests their preoperative use may reduce postoperative complications, but data specific to lumbar laminectomy are limited. Methods: We conducted a retrospective cohort study using the TriNetX research database to identify patients undergoing lumbar laminectomy over the past 20 years using Current Procedural Terminology (CPT) codes 63047 and 63048. Patients were stratified into 2 cohorts, those who used GLP-1 RAs within 1 year preoperatively and those who did not. Propensity score matching (PSM) was performed at a 1:1 ratio to balance demographics and medical comorbidities, including race, age at index surgery, gender, ethnicity, hypertension, diabetes, obesity, and other comorbidities. The primary outcomes were 180-day medical complications postoperatively. Using χ 2 analysis, risk ratios (RRs), 95% CI, and P values were calculated, with statistical significance at P P =0.0034) and a 43% reduction in all-cause mortality (0.8% vs. 1.4%, RR=0.551, 95% CI: 0.359–0.847, P =0.0058) compared with nonusers. Conclusions: Preoperative GLP-1 RA use is associated with a reduced postoperative risk of DVT and mortality in patients undergoing lumbar laminectomy. These findings suggest GLP-1 RAs may have a protective association in the postoperative period. Future prospective studies are warranted to validate these results and explore underlying mechanisms. Level of Evidence: Level III—retrospective, comparative cohort study.
- 29 June 2026
- Published by Wolters Kluwer Health in Clinical Spine Surgery
Preoperative Use of GLP-1 Receptor Agonists Is Associated With Reduced Risk of Postoperative DVT and Mortality in Patients Undergoing Lumbar Laminectomy
Study Design: Retrospective cohort study. Objective: To evaluate the association between preoperative glucagon-like peptide-1 receptor agonist (GLP-1 RA) use and postoperative outcomes in patients undergoing lumbar laminectomy. Summary of Background Data: GLP-1 RAs have gained prominence for their weight management benefits. Emerging evidence suggests their preoperative use may reduce postoperative complications, but data specific to lumbar laminectomy are limited. Methods: We conducted a retrospective cohort study using the TriNetX research database to identify patients undergoing lumbar laminectomy over the past 20 years using Current Procedural Terminology (CPT) codes 63047 and 63048. Patients were stratified into 2 cohorts, those who used GLP-1 RAs within 1 year preoperatively and those who did not. Propensity score matching (PSM) was performed at a 1:1 ratio to balance demographics and medical comorbidities, including race, age at index surgery, gender, ethnicity, hypertension, diabetes, obesity, and other comorbidities. The primary outcomes were 180-day medical complications postoperatively. Using χ 2 analysis, risk ratios (RRs), 95% CI, and P values were calculated, with statistical significance at P P =0.0034) and a 43% reduction in all-cause mortality (0.8% vs. 1.4%, RR=0.551, 95% CI: 0.359–0.847, P =0.0058) compared with nonusers. Conclusions: Preoperative GLP-1 RA use is associated with a reduced postoperative risk of DVT and mortality in patients undergoing lumbar laminectomy. These findings suggest GLP-1 RAs may have a protective association in the postoperative period. Future prospective studies are warranted to validate these results and explore underlying mechanisms. Level of Evidence: Level III—retrospective, comparative cohort study.
- 1 April 2026
- Published by Wolters Kluwer Health in JBJS Case Connector
- Vol. 16 (2)
Intercuneiform Instability Following Triplanar Tarsometatarsal Arthrodesis
Case: A 78-year-old man with osteoarthritis and progressive hallux valgus underwent triplanar first tarsometatarsal (TMT) arthrodesis using the Lapiplasty system. Despite successful fusion, postoperative radiographs demonstrated progressive intercuneiform diastasis with recurrence of deformity and midfoot discomfort. Conclusion: Intercuneiform instability may progress despite successful first TMT fusion and adjunct intercuneiform stabilization. In cases of ligamentous insufficiency, fixation alone may be inadequate, and supplemental intercuneiform fixation or arthrodesis should be considered.
- 1 April 2026
- Published by Wolters Kluwer Health in JBJS Case Connector
- Vol. 16 (2)
Intercuneiform Instability Following Triplanar Tarsometatarsal Arthrodesis
Case: A 78-year-old man with osteoarthritis and progressive hallux valgus underwent triplanar first tarsometatarsal (TMT) arthrodesis using the Lapiplasty system. Despite successful fusion, postoperative radiographs demonstrated progressive intercuneiform diastasis with recurrence of deformity and midfoot discomfort. Conclusion: Intercuneiform instability may progress despite successful first TMT fusion and adjunct intercuneiform stabilization. In cases of ligamentous insufficiency, fixation alone may be inadequate, and supplemental intercuneiform fixation or arthrodesis should be considered.
- 23 January 2026
- Published by Oxford University Press (OUP) in Journal of Burn Care & Research
- Vol. 47 (3) , 706-717
Prescription Analysis of Antihistamines’ Use in Patients With Moderate to Severe Burns
Postburn pruritus (PBP) significantly affects patients, causing discomfort and hindering recovery. Antihistamines, which block H1 receptors, are commonly prescribed for PBP, yet large-scale studies on their usage patterns are limited. This study evaluates antihistamine prescription trends and provider practices for PBP across varying burn severities from moderate to severe burns (≥20% TBSA). A treatment-pathways analysis was performed using TriNetX, a global, federated, deidentified database. Patients with burns ≥ 20% TBSA from the past 20 years (2004-2024) who developed pruritus were identified and stratified into 4 cohorts: 20%-40%, 40%-60%, 60%-80%, and ≥ 80% TBSA. The analysis evaluated trends in antihistamine prescriptions, including the number of patients treated with antihistamines, types prescribed, and median times to treatment initiation, duration, and therapy switching. The total sample included 2754 patients (20%-40% TBSA, n = 1712; 40%-60%, n = 613; 60%-80%, n = 253; ≥80%, n = 176). Over 70% received antihistamines, with hydroxyzine as the most common first-line therapy, followed by diphenhydramine. Across all cohorts, the average of the median times for initiation, therapy duration, and time before switching was 16.75 days, 90.25 days, and 27.75 days, respectively. Significant variations in the timing of therapy initiation suggest a gap in consistent symptom management during critical recovery periods, potentially affecting patient comfort and overall outcomes. These findings underscore the importance of vigilant postburn assessment, stepwise escalation based on response, and complementary strategies to optimize PBP management. Frequent switching and prolonged durations suggest a need for more effective and tailored therapeutic approaches to improve recovery outcomes for patients with burn injuries.
- 23 January 2026
- Published by Oxford University Press (OUP) in Journal of Burn Care & Research
- Vol. 47 (3) , 706-717
Prescription Analysis of Antihistamines’ Use in Patients With Moderate to Severe Burns
Postburn pruritus (PBP) significantly affects patients, causing discomfort and hindering recovery. Antihistamines, which block H1 receptors, are commonly prescribed for PBP, yet large-scale studies on their usage patterns are limited. This study evaluates antihistamine prescription trends and provider practices for PBP across varying burn severities from moderate to severe burns (≥20% TBSA). A treatment-pathways analysis was performed using TriNetX, a global, federated, deidentified database. Patients with burns ≥ 20% TBSA from the past 20 years (2004-2024) who developed pruritus were identified and stratified into 4 cohorts: 20%-40%, 40%-60%, 60%-80%, and ≥ 80% TBSA. The analysis evaluated trends in antihistamine prescriptions, including the number of patients treated with antihistamines, types prescribed, and median times to treatment initiation, duration, and therapy switching. The total sample included 2754 patients (20%-40% TBSA, n = 1712; 40%-60%, n = 613; 60%-80%, n = 253; ≥80%, n = 176). Over 70% received antihistamines, with hydroxyzine as the most common first-line therapy, followed by diphenhydramine. Across all cohorts, the average of the median times for initiation, therapy duration, and time before switching was 16.75 days, 90.25 days, and 27.75 days, respectively. Significant variations in the timing of therapy initiation suggest a gap in consistent symptom management during critical recovery periods, potentially affecting patient comfort and overall outcomes. These findings underscore the importance of vigilant postburn assessment, stepwise escalation based on response, and complementary strategies to optimize PBP management. Frequent switching and prolonged durations suggest a need for more effective and tailored therapeutic approaches to improve recovery outcomes for patients with burn injuries.
- Open Access
- 25 October 2025
- Published by SAGE Publications in Global Spine Journal
- Vol. 16 (4) , 1889-1897
Association Between Preoperative GLP-1 Receptor Analog Use and Postoperative Complications and Mortality Following Lumbar Fusion Surgery
Study Design: Retrospective Cohort Study. Objectives: This study evaluates the association between preoperative GLP-1 RA (glucagon-like-peptide-1 receptor antagonist) use and postoperative outcomes in patients undergoing lumbar fusion surgery. Methods: TriNetX database identified patients undergoing lumbar fusion within 20 years using Current Procedural Terminology (CPT). Patients were categorized by GLP-1 RA use within 1 year preoperatively. 1:1 propensity score match (PSM) balanced demographics and comorbidities including race/ethnicity, age, gender, hypertension, diabetes, obesity, nicotine dependence, sleep apnea, ischemic heart diseases, chronic kidney disease, acute kidney failure, mood disorders, asthma, chronic obstructive pulmonary disease, heart failure, alcohol dependence, anemia, and vitamin D deficiency. Primary outcomes were 1-year complications postoperatively. Chi-square analysis, risk ratios (RRs), 95% confidence intervals (CI), and P -values were calculated; significance was P < 0.05. Results: 4331 patients using preoperative GLP-1 RA were propensity score-matched with 179,268 controls without GLP-1 RA use, resulting in 4331 patients in each cohort after matching. At 1 year, GLP-1 RA users had significant reductions in DVT (1.4% vs 2.3%, RR = 0.64, 95% CI [0.464-0.883], P = 0.0061), PE (1.1% vs 1.6%, RR = 0.689, 95% CI [0.476-0.997], P = 0.0466), sepsis (4.0% vs 5.0%, RR = 0.811, 95% CI [0.66-0.995], P = 0.0447), all-cause mortality (2.1% vs 4.6%, RR = 0.46, 95% CI [0.36-0.589], P < 0.0001), pneumonia (2.4% vs 3.3%, RR = 0.716, 95% CI [0.548-0.936], P = 0.0139), and pseudoarthrosis (8.9% vs 13.8%, RR = 0.642, 95% CI [0.564-0.732], P < 0.0001) compared to non-users. Conclusions: Preoperative GLP-1 RA use is associated with a reduction in postoperative complications following lumbar fusion surgery. Further research is necessary to elucidate the underlying mechanisms and evaluate long-term outcomes.
- 25 October 2025
- Published by SAGE Publications in Global Spine Journal
- Vol. 16 (4) , 1889-1897
Open AccessAssociation Between Preoperative GLP-1 Receptor Analog Use and Postoperative Complications and Mortality Following Lumbar Fusion Surgery
Study Design: Retrospective Cohort Study. Objectives: This study evaluates the association between preoperative GLP-1 RA (glucagon-like-peptide-1 receptor antagonist) use and postoperative outcomes in patients undergoing lumbar fusion surgery. Methods: TriNetX database identified patients undergoing lumbar fusion within 20 years using Current Procedural Terminology (CPT). Patients were categorized by GLP-1 RA use within 1 year preoperatively. 1:1 propensity score match (PSM) balanced demographics and comorbidities including race/ethnicity, age, gender, hypertension, diabetes, obesity, nicotine dependence, sleep apnea, ischemic heart diseases, chronic kidney disease, acute kidney failure, mood disorders, asthma, chronic obstructive pulmonary disease, heart failure, alcohol dependence, anemia, and vitamin D deficiency. Primary outcomes were 1-year complications postoperatively. Chi-square analysis, risk ratios (RRs), 95% confidence intervals (CI), and P -values were calculated; significance was P < 0.05. Results: 4331 patients using preoperative GLP-1 RA were propensity score-matched with 179,268 controls without GLP-1 RA use, resulting in 4331 patients in each cohort after matching. At 1 year, GLP-1 RA users had significant reductions in DVT (1.4% vs 2.3%, RR = 0.64, 95% CI [0.464-0.883], P = 0.0061), PE (1.1% vs 1.6%, RR = 0.689, 95% CI [0.476-0.997], P = 0.0466), sepsis (4.0% vs 5.0%, RR = 0.811, 95% CI [0.66-0.995], P = 0.0447), all-cause mortality (2.1% vs 4.6%, RR = 0.46, 95% CI [0.36-0.589], P < 0.0001), pneumonia (2.4% vs 3.3%, RR = 0.716, 95% CI [0.548-0.936], P = 0.0139), and pseudoarthrosis (8.9% vs 13.8%, RR = 0.642, 95% CI [0.564-0.732], P < 0.0001) compared to non-users. Conclusions: Preoperative GLP-1 RA use is associated with a reduction in postoperative complications following lumbar fusion surgery. Further research is necessary to elucidate the underlying mechanisms and evaluate long-term outcomes.